FibroGen regains rights to anemia drug from AstraZeneca

(Reuters) – FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)